April 30, 2026 — Within days of semaglutide's compound patent expiry in India on March 20, 2026, nearly 13 pharmaceutical companies launched 26 different generic versions of the blockbuster GLP-1 receptor agonist. The rapid market entry has triggered a sweeping regulatory response from India's drug controller, with significant implications for API suppliers and CDMOs.
Companies including Sun Pharmaceutical, Dr. Reddy's, Zydus Lifesciences, Glenmark, and Alkem moved rapidly to secure CDSCO approvals and bring products to market. Dr. Reddy's received approval for its oral semaglutide through India's biosimilar pathway, based on a head-to-head study demonstrating non-inferiority to Novo Nordisk's Rybelsus. Eris Lifesciences partnered with Natco Pharma for a March 2026 launch.
Market share data reveals the immediate realignment: Mounjaro's share fell from 71% to 64%, while semaglutide's share rose from 25% to 33%. Eli Lilly's value share dropped from 61% to 56%.
India's CDSCO and Ministry of Health have launched an aggressive enforcement campaign targeting 49 entities across the distribution chain:
Quality and compliance premium: As regulators tighten oversight of finished dosage form supply chains, API suppliers with robust regulatory documentation, GMP-compliant facilities, and established quality systems gain competitive advantage.
Peptide API demand surge: India's generic wave drives massive demand for high-purity peptide API synthesis. CDMOs in India and China are scaling capacity, but regulatory scrutiny means suppliers must demonstrate process validation, impurity control, and batch consistency.
Biosimilar pathway precedent: Dr. Reddy's approval through India's biosimilar pathway — rather than the standard generic pathway — sets a precedent for how GLP-1 peptide drugs may be regulated in emerging markets. API suppliers should prepare for biosimilar-grade documentation requests.
Export opportunity: India's domestic launch platform positions suppliers for export to other markets. Sandoz has identified Canada and Brazil as near-term semaglutide opportunities, while India-based API producers prepare for global supply.
Novo Nordisk announced a €432M investment in its Athlone, Ireland facility to scale oral GLP-1 production. The company is also building a 1.2 million sq ft facility in North Carolina focused on semaglutide API synthesis. Meanwhile, Eli Lilly's Foundayo (orforglipron) — the first oral non-peptide GLP-1 approved under FDA's National Priority Voucher program — eliminates cold-chain requirements, potentially reshaping distribution economics.
For API suppliers, the diversification across injectable peptides, oral peptides, and oral non-peptide small molecules creates distinct supply chain requirements, each demanding different synthesis capabilities and regulatory pathways.
API suppliers should invest in scalable peptide synthesis capabilities, build regulatory-ready quality systems that satisfy FDA/EMA/CDSCO inspectors, prepare for oral GLP-1 demand with specialized formulation expertise, and monitor staggered patent expiries across markets to align capacity expansion with demand timing.
India's rapid generic semaglutide launch and CDSCO's crackdown represent a defining moment for the global GLP-1 supply chain. The market offers enormous growth potential — but only for suppliers who combine manufacturing scale with regulatory rigor. Quality, compliance, and supply chain transparency will be the decisive factors in capturing value.
